{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:38:21Z","timestamp":1776742701903,"version":"3.51.2"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K24 HL159246"],"award-info":[{"award-number":["K24 HL159246"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL134320"],"award-info":[{"award-number":["R01 HL134320"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268201700001I"],"award-info":[{"award-number":["HHSN268201700001I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jprot.2022.104788","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T12:29:54Z","timestamp":1670243394000},"page":"104788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study"],"prefix":"10.1016","volume":"272","author":[{"given":"Bruno","family":"Bohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Lutsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Pankow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faye L.","family":"Norby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Whitsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan T.","family":"Demmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jprot.2022.104788_bb0005","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jprot.2022.104788_bb0010","series-title":"Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003\u20132012. 8","author":"Gu","year":"2014"},{"key":"10.1016\/j.jprot.2022.104788_bb0015","doi-asserted-by":"crossref","first-page":"105,735","DOI":"10.1016\/j.biocel.2020.105735","article-title":"Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms","volume":"122","author":"Liberale","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jprot.2022.104788_bb0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jprot.2022.104788_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jprot.2022.104788_bb0030","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.jacc.2021.04.035","article-title":"The ARIC (Atherosclerosis Risk In Communities) Study: JACC Focus Seminar 3\/8","volume":"77","author":"Wright","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jprot.2022.104788_bb0035","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jprot.2022.104788_bb0040","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jprot.2022.104788_bb0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1373\/jalm.2018.027086","article-title":"Reproducibility and variability of protein analytes measured using a multiplexed modified aptamer assay","volume":"4","author":"Tin","year":"2019","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.jprot.2022.104788_bb0050","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in Ingenuity Pathway Analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jprot.2022.104788_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0378-4274(01)00268-5","article-title":"Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin","volume":"120","author":"Steiner","year":"2001","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jprot.2022.104788_bb0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hep.510270124","article-title":"Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities","volume":"27","author":"Honda","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jprot.2022.104788_bb0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MOL.0000000000000523","article-title":"Pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 inhibitors?","volume":"29","author":"Filippatos","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jprot.2022.104788_bb0070","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacl.2018.05.012","article-title":"PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?","volume":"12","author":"Mannarino","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.jprot.2022.104788_bb0075","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1074\/jbc.RA119.010221","article-title":"A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles","volume":"295","author":"Sarkar","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jprot.2022.104788_bb0080","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jprot.2022.104788_bb0085","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.biopha.2018.10.138","article-title":"The effects of proprotein convertase subtilisin\/kexin type 9 inhibitors on lipid metabolism and cardiovascular function","volume":"109","author":"Amput","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jprot.2022.104788_bb0090","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"Stroke prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.jprot.2022.104788_bb0095","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5551\/jat.RV17012","article-title":"Lipid lowering therapy and circulating PCSK9 concentration","volume":"24","author":"Nozue","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.jprot.2022.104788_bb0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-016-0604-3","article-title":"Statins and their effect on PCSK9\u2014impact and clinical relevance","volume":"18","author":"Taylor","year":"2016","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.jprot.2022.104788_bb0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nature10517","article-title":"Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B","volume":"479","author":"Vivian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jprot.2022.104788_bb0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1615\/CritRevImmunol.2013007409","article-title":"The yin-yang of KIR3DL1\/S1: molecular mechanisms and cellular function","volume":"33","author":"O\u2019Connor","year":"2013","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.jprot.2022.104788_bb0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12944-019-1052-1","article-title":"Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria","volume":"18","author":"Gao","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jprot.2022.104788_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2020.11.013","article-title":"Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation","volume":"315","author":"Reeskamp","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jprot.2022.104788_bb0125","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/1061186X.2019.1566342","article-title":"ANGPTL3: a novel biomarker and promising therapeutic target","volume":"27","author":"Jiang","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jprot.2022.104788_bb0130","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jacbts.2019.05.008","article-title":"Angiopoietin-like 3: from discovery to therapeutic gene editing","volume":"4","author":"Wang","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.jprot.2022.104788_bb0135","article-title":"Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study","volume":"zwaa152","author":"Hussain","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.jprot.2022.104788_bb0140","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jprot.2022.104788_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6578327","article-title":"Effects of angiopoietin-like 3 on triglyceride regulation, glucose homeostasis, and diabetes","volume":"2019","author":"Christopoulou","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.jprot.2022.104788_bb0150","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/oxfordjournals.jbchem.a003145","article-title":"Platelet-activating factor acetylhydrolase (PAF-AH)","volume":"131","author":"Arai","year":"2002","journal-title":"J. Biochem."},{"key":"10.1016\/j.jprot.2022.104788_bb0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0003319710375089","article-title":"In vitro and in vivo effects of statins on platelet-activating factor and its metabolism","volume":"62","author":"Tsantila","year":"2011","journal-title":"Angiology"},{"key":"10.1016\/j.jprot.2022.104788_bb0160","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/CIRCULATIONAHA.111.063487","article-title":"Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes","volume":"125","author":"Ryu","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jprot.2022.104788_bb0165","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1194\/jlr.E052886","article-title":"Unraveling the PAF-AH\/Lp-PLA2 controversy1","volume":"55","author":"Stafforini","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jprot.2022.104788_bb0170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2005.07.029","article-title":"Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration","volume":"186","author":"Zhang","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jprot.2022.104788_bb0175","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00041433-200406000-00015","article-title":"Platelet-activating factor acetylhydrolase: is it good or bad for you?","volume":"15","author":"Chen","year":"2004","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jprot.2022.104788_bb0180","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1194\/jlr.R045492","article-title":"To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase","volume":"55","author":"Marathe","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jprot.2022.104788_bb0185","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/infdis\/jiaa196","article-title":"Differential plasma protein regulation and statin effects in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients utilizing a proteomics approach","volume":"222","author":"deFilippi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jprot.2022.104788_bb0190","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0000000000001762","article-title":"Novel mediators of statin effects on plaque in HIV: a proteomics approach","volume":"32","author":"Defilippi","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.jprot.2022.104788_bb0195","doi-asserted-by":"crossref","first-page":"544,895","DOI":"10.3389\/fmolb.2020.544895","article-title":"PCOLCE is potent prognostic biomarker and associates with immune infiltration in gastric cancer","volume":"7","author":"Xiang","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.jprot.2022.104788_bb0200","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-4939-9095-5_14","article-title":"Procollagen C-proteinase enhancer 1 (PCPE-1) in liver fibrosis","volume":"1944","author":"Kessler","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jprot.2022.104788_bb0205","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.biocel.2005.10.007","article-title":"Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone","volume":"38","author":"Kessler-Icekson","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jprot.2022.104788_bb0210","article-title":"The role of CTHRC1 in regulation of multiple signaling and tumor progression and metastasis","volume":"9578701","author":"Mei","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jprot.2022.104788_bb0215","doi-asserted-by":"crossref","first-page":"108,594","DOI":"10.1016\/j.biopha.2019.01.055","article-title":"CTHRC1 promotes wound repair by increasing M2 macrophages via regulating the TGF-\u03b2 and notch pathways","volume":"113","author":"Qin","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jprot.2022.104788_bb0220","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3390\/ijms22052426","article-title":"The role of Collagen Triple Helix Repeat-Containing 1 Protein (CTHRC1) in rheumatoid arthritis","volume":"22","author":"Myngbay","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jprot.2022.104788_bb0225","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/CIRCULATIONAHA.119.044557","article-title":"Single-Cell RNA sequencing analysis reveals a crucial role for CTHRC1 (Collagen Triple Helix Repeat Containing 1) cardiac fibroblasts after myocardial infarction","volume":"142","author":"Ruiz-Villalba","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jprot.2022.104788_bb0230","article-title":"CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes","volume":"11, 19,873","author":"Sial","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jprot.2022.104788_bb0235","first-page":"635","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.jprot.2022.104788_bb0240","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1471-4159.2006.03878.x","article-title":"Identity of SMCT1 (SLC5A8) as a neuron-specific Na\u00a0+\u00a0\u2212coupled transporter for active uptake of L-lactate and ketone bodies in the brain","volume":"98","author":"Martin","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jprot.2022.104788_bb0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/1673-5374.264444","article-title":"Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging","volume":"15","author":"Nakanishi","year":"2019","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jprot.2022.104788_bb0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/09674845.2020.1810400","article-title":"Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14\u20133-3\u03b7 protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis","volume":"78","author":"Hu","year":"2021","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.jprot.2022.104788_bb0255","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.canlet.2019.02.035","article-title":"Cathepsin B: a sellsword of cancer progression","volume":"449","author":"Mijanovi\u0107","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jprot.2022.104788_bb0260","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ejvs.2010.01.030","article-title":"Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology","volume":"39","author":"Hurks","year":"2010","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.jprot.2022.104788_bb0265","article-title":"Simvastatin inhibits glucose metabolism and legumain activity in human myotubes","volume":"9","author":"Smith","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2022.104788_bb0270","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1189\/jlb.0812409","article-title":"HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activation","volume":"93","author":"Liao","year":"2013","journal-title":"J. Leukoc. Biol."}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391922003128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391922003128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:15:51Z","timestamp":1761740151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391922003128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":54,"alternative-id":["S1874391922003128"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2022.104788","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2022.104788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104788"}}